Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Immune Microenvironment

Katharina Sahm, MD

The D170 Microenvironment Team focuses on identification of immunotherapeutic targets within the central nervous system microenvironment with the goal to enhance the reactivity of the patient’s immune system against malignant brain tumors. Preclinical models as well as clinical samples of primary brain tumors and autoimmune encephalomyelitis are used to decipher cellular mechanisms of immune regulation within the CNS. Main research topics include the role of tumor blood vessels for activation, transmigration and effector function of antigen-specific T cells, the impact of kynurenine pathway metabolites and aryl hydrocarbon receptor signaling on tumor immunity as well as the development of immunotherapeutics for histone-3 mutant midline gliomas.

Current projects

  • Vascular control of tumor immunity in the CNS 
  • The role of CXCL10 in the immune regulation of melanoma and glioma 
  • Impact of aryl hydrocarbon receptor (AhR) signaling on immunity & AHR inhibitor development 
  • Advancing neoepitope-specific vaccines in Neurooncology 
  • A MultIceNTer PhasE I RNA VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3.3-Mutated Gliomas – INTERCEPT H3.3

Team Members

  • Katharina Sahm, MD - Team leader
  • Niklas Graßl, MD
  • Georgios Samaras, PhD student
  • Isabelle Bernhardt, MD student
  • Kristine Jähne - Technical Assistance

Selected Publications




to top
powered by webEdition CMS